Intercept Pharmaceuticals Gross Profit 2011-2021 | ICPT

Intercept Pharmaceuticals gross profit from 2011 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Intercept Pharmaceuticals Annual Gross Profit
(Millions of US $)
2020 $307
2019 $248
2018 $177
2017 $130
2016 $25
2015 $3
2014 $2
2013 $2
2012 $2
2011 $2
2010 $
Intercept Pharmaceuticals Quarterly Gross Profit
(Millions of US $)
2021-06-30 $96
2021-03-31 $81
2020-12-31 $83
2020-09-30 $78
2020-06-30 $75
2020-03-31 $72
2019-12-31 $69
2019-09-30 $61
2019-06-30 $66
2019-03-31 $52
2018-12-31 $52
2018-09-30 $46
2018-06-30 $43
2018-03-31 $36
2017-12-31 $37
2017-09-30 $41
2017-06-30 $31
2017-03-31 $21
2016-12-31 $14
2016-09-30 $5
2016-06-30 $6
2016-03-31 $0
2015-12-31 $0
2015-09-30 $0
2015-06-30 $0
2015-03-31 $1
2014-12-31 $0
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $0
2013-09-30 $0
2013-06-30 $0
2013-03-31 $0
2012-12-31 $0
2012-09-30 $1
2012-06-30 $1
2012-03-31 $1
2011-12-31
2011-09-30 $1
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.533B $0.313B
Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29